Overview

Conference: April 5-7 | In-Person

Join us for DIA's Global Pharmacovigilance and Risk Management Strategies Conference, the premier event for advancing your expertise in pharmacovigilance and regulatory affairs. Developed in collaboration with regulators and industry experts, this neutral forum provides unparalleled insights into global regulatory harmonization, AI-driven signal detection, and advanced safety analysis tools. At this conference, you’ll hear about updates, opportunities, and challenges shaping the future of drug safety and learn innovative problem-solving strategies that matter most to safety professionals. Attendees will gain actionable knowledge on integrating patient perspectives, optimizing Risk Management Plans (RMPs) and Risk Evaluation and Mitigation Strategies (REMS), and utilizing real-world evidence (RWE) for regulatory submissions and safety monitoring.

This conference also focuses on cutting-edge methodologies for signal detection, benefit-risk assessment, and addressing safety challenges in special populations. An opportunity not to miss to learn best practices for efficient pharmacovigilance operations, including adverse event reporting, outsourcing strategies, and compliance in resource-constrained settings. Register to attend and connect with industry leaders, regulatory authorities, and patient advocates to drive innovation, stay ahead in drug safety, and achieve excellence in regulatory compliance.

While we develop our 2027 agenda, please take a moment to review the 2026 Final Agenda.

Participant Testimonials

I have been attending for a number of years and the information has been very helpful in understanding challenges and updates impacting PV operations and Risk management/signaling. I appreciate all the work that goes into these presentations and putting together the Conference. – Donna Gesumaria, TG Therapeutics

DIA’s Global Pharmacovigilance Conference is an amazing meeting to attend! You’ll get updates on regulations, real case examples, and knowing other companies face the same challenges and share best practices is great to hear! I will be able to use information from this meeting in my daily work – Sharon Bathory, SpringWorks Therapeutics, Inc.

The DIA Global Pharmacovigilance and Risk Management Strategies Conference is one of the most valuable conferences I attend all year. The speakers bring a combination of deep regulatory insight and practical, real-world experience. – Katherine Phelan, Merck

Featured

Want to learn more about Global Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!

Who should attend?

Meeting Designed for
- Benefit-risk Assessment and Risk Management
- Clinical Research and Post-Market Studies
- Data Safety Monitoring, Analytics, and Safety Statistics
- Medical Affairs, Communications, Information, and Writing
- Medical Product Safety Assessment
- Patient Engagement and Advocacy Groups
- Pharmacoepidemiology
- Pharmacovigilance and Drug Safety
- Quality Assurance and Quality Control
- Real-World Evidence Generation
- Regulatory Affairs

Learning objectives

At the conclusion of this activity, participants should be able to:
- Integrate real-world data and evidence into safety evaluation and regulatory decision-making
- Discuss emerging technologies used in pharmacovigilance and safety monitoring
- Recognize approaches for communicating safety information and benefit–risk considerations
- Discuss strategies for addressing safety challenges in special populations and small organizations
- Summarize key global regulatory and policy updates in pharmacovigilance and risk management
- Apply structured approaches to REMS, aRMMs, and benefit–risk frameworks

Program Committee

Bethany Van Veen CEO and Founder
Perspective Pharmacovigilance, United States
Scott Janiczak, PharmD, MPH Team Leader, Division of Pharmacovigilance-I, OSE, CDER
FDA, United States
Ranjeeta Sinvhal, MD Executive Medical Director, Medical Safety
AbbVie, United States
Michael Forstner, PhD, MPH, MSc Managing Director, Head of Pharmacoepidemiology Practice
Switzerland
Balmeet Gurm, MD Executive Director, Therapeutic Area Lead Cardiovascular and EBs, Patient Safety
Bristol Myers Squibb, United States
Tarek Hammad, MD, PhD, MS, MSc, FISPE Vice President, Global Head of Medical Safety, Marketed Products and PDT, PSPV
Takeda Pharmaceuticals, United States
Stephanie Millican, PhD, MSc Deputy Director Benefit Risk Evaluation, Safety and Surveillance
MHRA, United Kingdom
Kal Elhoregy, RPh Senior Director, Global Risk Management & Pharmacovigilance Compliance
Amneal Pharmaceuticals, United States
Jamie Wilkins, PharmD Head, Risk Management Center of Excellence
Pfizer Inc, United States
Vanessa Zapata Associate Director, Global Clinical Safety & Pharmacovigilance Training Lead
Merck & Co., Inc., Canada
Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Patient Safety Officer
Bristol Myers Squibb, United States
Mark Perrott, PhD Managing Partner
Axian Consulting Ltd., United Kingdom